Overview

Proof that an oral peptide drug can work well — by not being absorbed at all. Linaclotide acts entirely on the luminal surface of the gut and is essentially undetectable in blood, which sidesteps the systemic side effects that limit most peptides.

FDA ApprovedFDA-approved for irritable bowel syndrome with constipation and for chronic idiopathic constipation, including a pediatric indication.

At a glance

Regulatory status	FDA-approved for irritable bowel syndrome with constipation and for chronic idiopathic constipation, including a pediatric indication.
Drug class	Guanylate cyclase-C agonist — 14-amino-acid peptide with three disulfide bridges
Route	Oral capsule, once daily
Half-life	Minimally absorbed — acts locally in the gut lumen
Evidence rating	5/5 Very strong Evidence rating 5 out of 5: Very strong Multiple phase 3 randomized trials plus regulatory approval in a major market.
Studied in	Multiple phase 3 trials in IBS-C and chronic idiopathic constipation; a dedicated pediatric functional constipation program.

How it works

Agonises guanylate cyclase-C on the luminal surface of intestinal epithelium, raising intracellular and extracellular cyclic GMP. That increases chloride and bicarbonate secretion, drawing fluid into the lumen and accelerating transit. Extracellular cGMP also reduces visceral afferent nociceptor firing, which explains the pain benefit that laxatives do not provide.

Evidence base

Rated 5 of 5 — Very strong. Multiple phase 3 randomized trials plus regulatory approval in a major market.

Multiple replicated phase 3 trials with patient-reported endpoints agreed with regulators in advance.

Benefits & potential uses

Bars indicate how well each claim is supported: three = strong human evidence, two = moderate, one = preliminary or preclinical.

Relieves both constipation and abdominal pain Strong evidence

The visceral analgesic effect is mechanistically distinct from the laxative effect, and is what separates it from osmotic laxatives.
Essentially no systemic exposure Strong evidence

Plasma concentrations are generally below the limit of quantification, which largely removes systemic drug interactions.
Consistent phase 3 results Strong evidence

Replicated across multiple trials in both indications with validated symptom endpoints.
Pediatric indication Strong evidence

Approved for functional constipation in children within a defined age range, supported by its own trial.

Risks, cons & cautions

Bars indicate seriousness: three = serious or common, two = moderate, one = minor.

Boxed warning: contraindicated in young children Serious

Contraindicated under 2 years of age due to fatal dehydration in juvenile animal studies. This is an absolute contraindication, not a caution.
Diarrhea Moderate evidence

The most common adverse effect and the main reason for discontinuation — an on-target consequence of the mechanism.
Severe diarrhea and dehydration Serious

Can be serious in the elderly or in anyone unable to maintain fluid intake; the drug should be stopped.
Contraindicated in mechanical obstruction Serious

Increasing intestinal secretion behind an obstruction is dangerous.
Abdominal pain, bloating and flatulence Minor

Common early in treatment.

Who should avoid it

Children under 2 years — boxed warning
Known or suspected mechanical gastrointestinal obstruction
Severe dehydration

If used under medical supervision, monitor

Stool frequency and consistency
Hydration status, particularly in elderly patients
Symptom response at 4–12 weeks

Interactions

Not exhaustive. Always have a pharmacist or physician review your full medication list — including supplements.

Minimal — negligible systemic absorption means essentially no pharmacokinetic drug interactions
Other laxatives — additive diarrhea risk

Commonly confused with

These mix-ups cause real harm — two products sold under one name, or two molecules whose effects run in opposite directions.

Plecanatide FDA Approved Evidence 4/5

Same target and same indications. Plecanatide is modelled on uroguanylin and is pH-sensitive, which is claimed to concentrate activity in the small intestine and reduce diarrhea rates.

Compare side by side

Regulatory & legal status

Prescription drug.

Infographic

Linaclotide — benefits & risks at a glance Download SVG

Where to read further

We link to live literature searches rather than a frozen citation list, so you always see current results — including anything published after our last review.

IBSconstipationoral peptideapprovedgut

Related peptides in Gut & Gastrointestinal

Terms used on this page

Oral Peptide Delivery: Oral peptide delivery is the formulation of a peptide into a swallowed dosage form, a route that fights gastric acid, gut proteases and an epithelium built to exclude large molecules.
Adverse Drug Reaction (ADR): An adverse drug reaction is a noxious, unintended response to a medicine given at normal doses, and unlike an adverse event the term carries a causal judgement inside it.
Good Manufacturing Practice (GMP): Good manufacturing practice is the enforceable quality system governing how a drug is made, requiring qualified facilities, validated processes and documented control of every batch.
Phase 3 Trial: A Phase 3 trial is the large confirmatory study, powered for a prespecified clinical endpoint, on which a marketing application and the resulting product label are built.
Drug-Drug Interaction (DDI): A drug-drug interaction is a change in one medicine's exposure or effect caused by another, arising pharmacokinetically through absorption or metabolism, or pharmacodynamically at the effect site.
Contraindication vs Precaution: A contraindication marks a situation where a drug must not be used at all, while a precaution flags a risk that calls for caution, monitoring or a modified plan rather than avoidance.

This page is educational information, not medical advice. It cannot account for your medical history, medications, or risk factors. Do not start, stop or change any treatment based on it. Speak to a qualified healthcare professional who knows your case.